FDA Grants Fast Track Status to NUC-1031 for Biliary Tract Cancer
OncLive,
The FDA has granted a fast track designation to the first-in-class nucleotide analogue NUC-1031 for use as a potential…
PRO-105, a phase II open-label study of NUC-1031 in patients with platinum-resistant ovarian cancer.
Overview of attention for article published in Journal of Clinical Oncology, May 2018
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
Good Attention Score compared to outputs of the same age (73rd percentile)
-
Above-average Attention Score compared to outputs of the same age and source (55th percentile)
Readers on
- mendeley
- 4 Mendeley